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Malaria remains a global health calamity, with an esti-mated 212 million cases and 429,000 deaths1 in 2015, that occurs mostly in sub-Saharan Africa and results 
from infection with the Apicomplexan parasite Plasmodium falci-
parum (Pf). Improved malaria treatment and control has reduced 
morbidity and mortality worldwide by 40–50% since 2000 (ref. 1), 
due largely to highly effective artemisinin-based combination 
therapies and mosquito vector control measures1,2. An important 
strategy to further advance the malaria elimination agenda is to 
include transmission-blocking agents in combination therapies3. 
Such agents inhibit the development of parasite gametocytes 
(GAMs), which represent an alternative form of intra-erythro-
cytic development to the pathogenic asexual blood stage (ABS) 
parasites and that mature over five stages4. Only stage V GAMS, 
which may survive days to weeks in circulation5, can continue 
the Pf lifecycle in Anopheles mosquitoes following ingestion of 
a parasitized blood meal. In the mosquito midgut, male GAMs 
exflagellate and produce microgametes that can fuse with female 
macrogametes to produce zygotes. Following subsequent devel-
opment as ookinetes and oocysts, sporozoites are formed. Once 
inoculated in a new host, they will develop in the liver and initiate 
a new ABS cycle6.
Primaquine is currently the only available drug with potent 
activity against stage V GAMs7,8, but it can be toxic for glucose-
6-phosphate dehydrogenase-deficient patients8. Hence, there is 
a compelling need to develop alternative transmission-blocking 
drugs. Recent advances in GAM-specific high-throughput screen 
technology9–19, combined with functional validation assays and 
drug action/resistance studies19–21, provide a powerful foundation to 
identify leads with Pf transmission-blocking activity.
In this study, we report a screen of the Novartis-GNF (The 
Genomics Institute of the Novartis Research Foundation) Malaria 
Box of ABS-active compounds22 on Pf GAM stages and describe 
the identification and antimalarial properties of hexahydroquino-
lines (HHQs), a chemical class with considerable transmission-
blocking potential.
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Antimalarial compounds with dual therapeutic and transmission-blocking activity are desired as high-value partners for com-
bination therapies. Here, we report the identification and characterization of hexahydroquinolines (HHQs) that show low 
nanomolar potency against both pathogenic and transmissible intra-erythrocytic forms of the malaria parasite Plasmodium 
falciparum. This activity translates into potent transmission-blocking potential, as shown by in vitro male gamete formation 
assays and reduced oocyst infection and prevalence in Anopheles mosquitoes. In vivo studies illustrated the ability of lead HHQs 
to suppress Plasmodium berghei blood-stage parasite proliferation. Resistance selection studies, confirmed by CRISPR–Cas9-
based gene editing, identified the digestive vacuole membrane-spanning transporter PfMDR1 (P. falciparum multidrug resis-
tance gene-1) as a determinant of parasite resistance to HHQs. Haemoglobin and haem fractionation assays suggest a mode of 
action that results in reduced haemozoin levels and might involve inhibition of host haemoglobin uptake into intra-erythrocytic 
parasites. Furthermore, parasites resistant to HHQs displayed increased susceptibility to several first-line antimalarial drugs, 
including lumefantrine, confirming that HHQs have a different mode of action to other antimalarials drugs for which PfMDR1 is 
known to confer resistance. This work evokes therapeutic strategies that combine opposing selective pressures on this parasite 
transporter as an approach to countering the emergence and transmission of multidrug-resistant P. falciparum malaria.
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Results
Identifying HHQs as potent gametocytocidal inhibitors. Using 
a luciferase (LUC)-based assay, we screened 3,825 compounds 
from the Novartis-GNF Malaria Box for activity against NF54Pfs16 
early-stage GAMs. This screen yielded 797 compounds exhibiting 
≥ 50% inhibition at 2.6 μ M. Re-screening confirmed activity for 
683 compounds, of which 176 showed ≥ 50% inhibition at 0.65 μ M 
(Fig. 1a). Screening the Novartis-GNF Malaria Box against late-stage 
GAMs using high-content imaging identified 572 hits with ≥ 50% 
inhibition at 2 µ M in at least two of the three replicates (Fig. 1a and 
Supplementary Fig. 1a).
Late-stage gametocytocidal hits were then prioritized for half-
maximum inhibitory concentration (IC50) determination using both 
early- and late-stage GAM assays. Limited availability restricted the 
number of compounds to 149 (Supplementary Fig. 1b), yielding 71 
and 60 compounds with IC50 values below 1 µ M for early- and late-
stage GAMs, respectively (Supplementary Table 1). Among these, 
20 early-GAM and 16 late-GAM active compounds had IC50 values 
of ≤ 200 nM. In total, 43 compounds showed sub-micromolar activ-
ity against both stages (Fig.  1b). Reference drug controls showed 
expected values (Supplementary Table 2).
After deprioritizing chemical classes related to current antima-
larial drugs or having liabilities likely to impede potential devel-
opment, we identified four compounds with potent early- and 
late-stage gametocytocidal activity: GNF-Pf-5640, GNF-Pf-5660, 
GNF-Pf-5668 and GNF-Pf-5310 (Fig.  1c and Supplementary 
Table 3). These compounds also showed potent ABS activity (IC50 
values < 25 nM) against drug-sensitive 3D7 and multidrug-resistant 
Dd2 parasites, including a PfATP4 mutant line (Supplementary 
Fig.  2 and Supplementary Table  3). GNF-Pf-5640, GNF-Pf-5660 
and GNF-Pf-5668 share a common scaffold belonging to the HHQ 
class of compounds (Fig.  1d), whereas GNF-Pf-5310 is a musca-
rinic-like compound (Supplementary Fig.  3). Cytotoxicity assays 
showed no inhibition at 40 μ M with GNF-Pf-5660, while the other 
three compounds caused < 50% inhibition at that concentration 
(Supplementary Fig. 2), indicating minimal toxicity against mam-
malian cells.
HHQs demonstrate potent in vitro transmission-blocking 
activity. Using an in vitro Pf dual gamete formation assay (DGFA), 
we investigated whether these four potent GAM-active compounds 
would also inhibit the development of cultured female and male 
gametes. The results indicated a potent inhibitory effect of the three 
HHQs on exflagellation when GAMs were exposed for 24 h and 
the compound carried over during the subsequent period of male 
gamete induction (‘carry-over’, Table 1). This effect persisted when 
compounds were washed out after 24 h, that is, before gamete 
induction (‘wash-out’, Table  1). HHQs were thus effective against 
both mature male GAMs and developing male gametes, but showed 
no activity on female gamete formation. The muscarinic-like com-
pound GNF-Pf-5310 showed no activity against either male or 
female gametes, contrasting with our transmission-blocking control 
methylene blue23,24 (Table 1).
GNF-Pf-5660, GNF-Pf-5668 and GNF-Pf-5310 were also tested 
in a membrane-feeding assay using Anopheles stephensi mosqui-
toes. This assay more closely mimics the natural parasite lifecycle 
than the DGFA, because compound-exposed Pf GAMs initiate the 
entire mosquito vector cycle from gametes to midgut oocysts. Pre-
treatment of GAMs with GNF-Pf-5660 or GNF-Pf-5668 at 3× their 
late-stage IC50 caused a 97% and 57% reduction, respectively, in the 
infection prevalence (that is, the percentage of infected mosquitoes, 
Fig. 2a), whereas the oocyst density per infected mosquito midgut 
was reduced by 95–99% (Fig. 2b). GNF-Pf-5660- and GNF-Pf-5668-
exposed GAM cultures used for feeding to A. stephensi showed a 98% 
and 70% reduction, respectively, in their male GAM exflagellation 
rates (Fig. 2c), confirming earlier DGFA results. GNF-Pf-5310 was 
less active at similar exposure levels, causing no reduction in infec-
tion prevalence, a 73% reduction in oocyst density, and no effect on 
male GAM exflagellation rates (Fig. 2). As a result, GNF-Pf-5310 
was deprioritized for further studies. The positive control methy-
lene blue displayed maximal transmission-blocking activity (Fig. 2). 
Pre-treatment of GAMs with compounds at 1× their late-stage IC50 
caused a lower to no effect on the parameters assessed (Fig. 2 and 
Supplementary Table  4a). The vehicle control DMSO showed no 
reductions compared to untreated controls.
In vivo activity of HHQs. HHQ antimalarial activity was assayed 
in Plasmodium berghei (Pb)-infected mice using the 4-day Peters 
test25. Intraperitoneal injection of 70 mg kg–1 of GNF-Pf-5660 or 
GNF-Pf-5668 reduced parasitaemias by 22% or 43%, respectively, 
compared to vehicle-treated mice (Fig.  2d). At 100 mg kg–1, these 
agents reduced parasitaemia by 65% and 91%, respectively (Fig. 2d 
and Supplementary Table 4b). To assess the in vivo transmission-
blocking activity of HHQs, infected mice were administered only 
two 100 mg kg–1 doses of GNF-Pf-5660 or GNF-Pf-5668. Following 
blood meals on GNF-Pf-5660-dosed mice, we observed a 25% and 
21% reduction in the number of infected mosquitoes and their 
oocyst burdens, respectively (Fig.  2a,b). No effect was observed 
in the GNF-Pf-5668 mosquito cohort, although it displayed a 31% 
reduction in the number of male exflagellation centres at the time 
of mosquito feeding (Fig. 2c and Supplementary Table 4c). Limited 
in vivo transmission-blocking activity, as compared with our in 
vitro results, was also observed upon treating mice with two doses 
of dihydroartemisinin (DHA). Those assays showed 65% and 75% 
reductions in the number of infected mosquitoes and the oocyst 
burden, respectively, and found no reduction in the numbers of 
male exflagellation centres (Fig.  2a–c). These data are consistent 
with this two-dosing regimen having less impact on ABS parasitae-
mia than the 4 days of dosing used in the Peters test (Fig. 2d).
Resistance to HHQs is mediated by mutations in PfMDR1 and 
results in sensitization to clinical antimalarials. To gain insight 
into the mode of action of HHQs, we selected for Pf ABS resistance 
in vitro in the Dd2-B2 parasite line (the B2 clone of the Dd2 line), 
an approach that has proven effective for multiple antimalarial 
agents26. Whole-genome sequence analysis of the resulting resistant 
clones identified the PfMDR1 (P. falciparum multidrug resistance 
gene-1) S1075I mutation in the GNF-Pf-5640-selected clone 2C4C3 
and PfMDR1 Y290F in the GNF-Pf-5640-selected clone 3H9C7. 
These resistant clones showed a 77- and 79-fold increase in IC50 val-
ues for GNF-Pf-5640 compared to the parental Dd2-B2 line, respec-
tively (Fig. 1e). The allele balance (AB) of the mutations in these 
clones was 50–59%, consistent with their acquisition in one of the 
two pfmdr1 copies present in Dd2-B2. The GNF-Pf-5660-selected 
clone 2B6H1 and the GNF-Pf-5668-selected clone 3C4D2 showed 
IC50 increases of 248- and 37-fold, respectively, and had acquired the 
PfMDR1 Y290F (AB 100%) or F1072L (AB 67%) mutations, respec-
tively (Fig. 1e). Shifts in IC90 values were similar to IC50 increases 
(Supplementary Tables 5 and 6).
Whole-genome sequencing data indicated that the GNF-Pf-
5668-selected 3C4D2 clone also carried four copies of pfmdr1, con-
sistent with further gene amplification compared to the Dd2-B2 
parent (which has two pfmdr1 copies in tandem). We were unable 
to determine whether the F1072L mutation (AB 67%) was mainly 
located in the additional amplicons. Susceptibility testing of resis-
tant clones indicated that each of the three observed PfMDR1 muta-
tions conferred cross-resistance to all HHQs (Fig. 1e).
Because HHQ resistance was the highest in lines harbouring 
the Y290F mutation, we used a previously derived NF54 line27 that 
harboured this mutation (NF54selY290F) to verify whether Y290F 
also conferred resistance at the GAM stage. NF54selY290F early-stage 
GAMs showed a 40–74-fold IC50 shift for all HHQs compared to 
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Fig. 1 | Identifying HHQs as potent Pf AbS and GAM inhibitors. a, Outcomes of the primary screening of the GNF-Novartis Malaria Box library against 
early- and late-stage Pf NF54Pfs16 GAMs, using luciferase-based and high-content imaging assays, respectively. Compounds were classified based on the 
concentration at which 50% inhibitory activity was achieved. b, Scatterplot of early- and late-stage gametocytocidal potency of 63 compounds with dual 
activity (expressed as pIC50 values, which equal − log(IC50), where a value of 9 corresponds to 10−9 M, that is, 1 nM). Red stars correspond to the four 
compounds selected for the study. Data are based on two independent experiments, each probing both early- and late-stage GAMs. c, Intra-erythrocytic 
stage-specific activity of the four selected compounds was obtained from two independent experiments for each parasite stage (Supplementary Table 3). 
d, Structure of the three HHQs confirmed to have transmission-blocking activity. e, Impact of PfMDR1 mutations and copy number on HHQ potency. 
The x axis depicts the individual mutant lines and their wild-type parental lines and indicates the GNF-Pf compound number, the clone number, and in 
parentheses the PfMDR1 mutation and its allele balance. ‘Edited’ implies that the Dd2-B2 line was edited using a CRISPR–Cas9 system to introduce the 
designated PfMDR1 mutation. Mean ±  s.e.m. IC50 values were calculated from three or more independent experiments (for details see Supplementary 
Table 5) and significance was assessed by a Welch’s corrected t-test with Bonferroni–Dunn adjusted P values for multiple comparisons when  
applicable: ***P <  0.001, ****P <  0.0001.
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wild-type NF54 (Supplementary Table 7). High levels of resistance 
were also observed at the late GAM stage, but because only very low 
numbers of NF54selY290F late GAMs could be obtained, accurate late-
stage IC50 values could not be calculated.
Structural modelling of PfMDR1 localized amino acid residue 
290 to transmembrane domain (TMD) 5 and residues 1072 and 1075 
to TMD 12. All three residues resided in the predicted drug-binding 
pocket cavity of PfMDR128, where they might mediate contact with 
substrates (Fig.  3a,b). Docking studies suggested that each muta-
tion could significantly alter transporter interactions with HHQs. 
Interestingly, F1072L and Y290F seemed to decrease the minimum 
estimated energy required for docking (Supplementary Tables 8–12 
and Supplementary Fig.  4). This effect was less pronounced for 
S1075I, which could be due to this residue not being fully exposed 
to the drug-binding pocket.
To test whether these point mutations in PfMDR1 were causal 
for resistance, we implemented a pfmdr1-specific CRISPR–Cas9 
strategy27. Transfection of parental Dd2-B2 parasites yielded the 
PfMDR1edF1072L and PfMDR1edS1075I clones that expressed the F1072L 
and S1075I mutations, respectively, observed in both pfmdr1 copies. 
These clones showed an essentially equivalent gain of resistance to 
HHQs as the original drug-pressured lines, confirming the causal 
role of the PfMDR1 mutations in mediating resistance (Fig.  1e). 
Despite repeated efforts, we were unable to introduce the Y290F 
mutation into the parental line.
Testing KD1mdr1, a pfmdr1 knockdown line previously generated 
in FCB parasites, showed that a decreased pfmdr1 copy number did 
not affect HHQ susceptibility (Fig. 1e). Similarly, increased pfmdr1 
copy number also did not noticeably affect HHQ susceptibility 
(Fig. 1e), as shown by the similar IC50 values of GNF-Pf-5668-3C4D2 
(harbouring an estimated four copies of pfmdr1 in addition to the 
F1072L mutation) and PfMDR1edF1072L (with the F1072L mutation 
engineered into the wild-type Dd2-B2 line with two pfmdr1 copies).
The impact of the three PfMDR1 mutations on Pf ABS suscepti-
bility to known antimalarials was determined using PfMDR1edF1072L, 
PfMDR1edS1075I and GNF-Pf-5660-2B6H1 (also referred to as 
PfMDR1selY290F) (Fig.  3c). For all three lines, no changes in sus-
ceptibility were observed for piperaquine, chloroquine (CQ), the 
active metabolite monodesethyl-CQ (md-CQ), md-amodiaquine 
(md-ADQ) or ferroquine (Fig.  3 and Supplementary Tables  13  
and 14). In contrast, PfMDR1edF1072L and PfMDR1selY290F showed 
a higher susceptibility to both quinine (QN) (3.6- and 3.7-fold, 
respectively) and mefloquine (MQ) (3.6- and 2.0-fold, respec-
tively), whereas PfMDR1edS1075I showed a 5.1-fold increased QN 
susceptibility but only a 1.4-fold increased susceptibility to MQ. 
Lumefantrine (LMF) showed a similar trend, with PfMDR1edF1072L 
and PfMDR1selY290F showing a higher LMF susceptibility (3.1- and 
1.9-fold, respectively), whereas PfMDR1edS1075I remained unchanged. 
All three mutations significantly increased Pf susceptibility to DHA 
by ~1.6-fold. Parasite susceptibility to the experimental ACT-
451840 compound, a known inhibitor of PfMDR127, was decreased 
by 16-, 5.5- and 45-fold for PfMDR1edF1072L, PfMDR1edS1075I and 
PfMDR1selY290F, respectively (Fig. 3c).
To assess the effects of pfmdr1 copy number variation in com-
bination with the F1072L mutation, we compared the antima-
larial susceptibilities of GNF-Pf-5668-3C4D2 (harbouring four 
pfmdr1 copies + F1072L (AB 69%)) to that of PfMDR1edF1072L (with 
two pfmdr1 copies + F1072L (AB 100%)). The results indicated 
a decreased susceptibility to QN, MQ and LMF (that is, higher 
IC50 values) in GNF-Pf-5668-3C4D2 compared to PfMDR1edF1072L 
(Fig. 3c). Importantly, these pfmdr1 copy number-induced changes 
in GNF-Pf-5668-3C4D2 did not fully compensate for the effects 
introduced by the F1072L mutation, as this line still showed a 
increased susceptibility to QN (1.7-fold) and MQ (1.4-fold) com-
pared to the wild-type Dd2-B2 control (Fig. 3c). These data provide 
evidence that the F1072L mutation had a major effect on increasing 
parasite susceptibility to QN, MQ and LMF that was only partially 
reversed by increases in pfmdr1 copy number.
HHQs inhibit haemoglobin endocytosis. Previous studies have 
shown that mutant PfMDR1 isoforms can modulate the degree of 
Pf ABS resistance to several antimalarial drugs, including CQ and 
ADQ, in lines expressing mutant pfcrt29–31. These 4-aminoquinolines 
are known to inhibit haemozoin (Hz) formation and cause a build-
up in free haem32,33. In light of the finding that PfMDR1 confers Pf 
resistance to HHQs, we performed subcellular haem fractionation 
assays to assess whether these agents might also affect Hz formation 
in ABS parasites (Fig. 4 and Supplementary Table 15).
In parental Dd2-B2 parasites, we observed that haemoglo-
bin (Hb) and free haem concentrations per parasite remained 
unchanged across all GNF-Pf-5660 exposure levels (up to 2× IC50) 
(Fig. 4). Hz levels, however, showed a 1.5-fold decrease when para-
sites were exposed to as little as 0.1× the GNF-Pf-5660 IC50 value, 
as compared with untreated controls. A 2.3-fold reduction in Hz 
levels was observed at higher exposure levels (0.25× to 2× IC50, 
Fig. 4). Total haem iron levels also showed similar reductions with 
increasing concentrations of GNF-Pf-5660 (Fig. 4). A similar profile 
of reduced Hz and total haem iron content per parasite was also 
observed in PfMDR1selY290F, albeit at > 160-fold higher GNF-Pf-5660 
exposure levels than in Dd2-B2, consistent with the fold increase in 
IC50 in the mutant line (Fig. 4).
For comparison, we also assessed the haem fractionation pro-
files of MQ and LMF. In the Dd2-B2 line, MQ and LMF showed 
little or no effect compared to untreated controls, with the excep-
tion of a 1.6-fold decrease in Hz levels in parasites exposed to 
2× the MQ IC50. Intriguingly, PfMDR1selY290F showed MQ profiles 
similar to those observed with GNF-Pf-5660, that is, reductions in 
Hz and total haem iron levels with increasing MQ concentrations. 
In PfMDR1selY290F, LMF also caused a reduction in Hz and total haem 
iron amounts at 1× to 2× IC50 concentrations (Fig. 4).
We also measured the amount of Hb endocytosed by late rings 
exposed to GNF-Pf-5660, WR99210, MQ or LMF, using western 
Table 1 | Gamete formation inhibitory effect of the four selected compounds
Mean IC50 (lower 95% CI – upper 95% CI)
Male carry-over Female carry-over Male wash-out Female wash-out
GNF-Pf-5640 86.0 nM (22.0–335.1) > 20 μ M 521.3 nM (447.3–607.6) > 20 μ M
GNF-Pf-5660 67.7 nM (40.9–112.2) > 20 μ M 264.2 nM (142.8–488.7) > 20 μ M
GNF-Pf-5668 88.8 nM (53.0–148.8) > 20 μ M 138.8 nM (67.0–287.5) > 20 μ M
GNF-Pf-5310 > 20 μ M > 20 μ M > 20 μ M > 20 μ M
Methylene blue 61.5 nM (38.8–97.3) 161.8 nM (111.4–234.9) 146.7 nM (116.3–185.1) 846.2 nM (490.6–1,460.0)
Compounds were carried over from GAM exposure to induction of gamete formation in the carry-over format of the assay, but were washed out before gamete formation in the wash-out format of the 
assay. CI: 95% confidence interval based on four biological replicates.
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blot analysis of wild-type Dd2-B2 or HHQ-resistant PfMDR1selY290F 
parasites (Fig. 5 and Supplementary Table 16). Results showed that 
the Hb levels within parasites were reduced by 32% in GNF-Pf-
5660-exposed Dd2-B2, but remained unchanged in PfMDR1selY290F. 
Dd2-B2 parasites showed no significant changes in Hb levels when 
exposed to WR99210, MQ or LMF.
Discussion
Here, we describe the antimalarial properties of HHQs, a class of 
potent gametocytocidal antimalarials with ABS activity that were 
identified by screening the Novartis-GNF Malaria Box against 
early- and late-stage Pf GAMs. Functional assays with Pf GAMs and 
gametes confirmed potent transmission-blocking activity. Moderate 
activity with our initial hits was also observed in vivo in Pb mouse 
models. Mode of action and resistance studies implicated a key role 
for the digestive vacuole (DV) transporter PfMDR1. We also pro-
vide evidence that HHQs reduce levels of Hz and total haem iron 
in treated parasites and inhibit the initial uptake of Hb from host 
red blood cells (RBCs). Cross-resistance assays also revealed that 
HHQ-resistant parasites became sensitized to several antimalarials 
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in current clinical use, emphasizing the potential added value of 
HHQs for combination treatments.
The confirmed hit rates of 18% and 15% obtained from our 
compound screens of early- and late-stage GAMs, respectively 
(Fig.  1a), highlight the value of screening ABS-active compound 
libraries as a source for identifying gametocytocidal compounds. 
The limited overlap (20%) between early- and late-stage GAM 
hits (Supplementary Figure  1b) suggests that GAMs at different 
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developmental stages express distinct sets of druggable targets, pro-
vided that technology-related differences such as incubation times, 
sensitivity or specific bias for selecting certain chemical classes were 
minimal in both screens.
Our HHQ hits GNF-Pf-5640, GNF-Pf-5660 and GNF-Pf-5668 
showed potent activity against ABS parasites as well as early- and late-
stage GAMs (Fig. 1c), with only minimal toxicity against mammalian 
cells. These compounds were inactive against cultured Pb liver- 
stage parasites16, possibly because Hb import and metabolism does 
not occur in parasitized hepatocytes.
The results provided herein also document potent in vitro 
HHQ activity on male GAMs and gametes, which translated into 
marked transmission-blocking activity in mosquitoes (Table 1 and 
Fig. 2). In Pb-infected mice, HHQs showed moderate efficacy: the 
4-day Peters tests indicated a potent inhibition of ABS growth at 
100 mg kg–1, whereas the two-dose assay showed only a limited 
impact on ABS parasitaemia and parasite transmission (Fig. 2). The 
high doses required in vivo, compared to the lower doses at which 
activity was observed in vitro, suggest that HHQs might be rapidly 
metabolized or otherwise inactivated or eliminated by the host. The 
ester group present in HHQs, for instance, is probably sensitive to 
host esterases34. These HHQs are the first hits from this class and 
structure–activity relationship studies and chemical optimization 
will be required. Enhancing HHQ transmission-blocking activity 
in vivo is an important goal, in light of the limited efficacy observed 
to date (Fig. 2). We note that earlier studies of Pb reported that a 
30% reduction in oocyst numbers per infected mosquito sufficed to 
eliminate the parasite from a murine population after several trans-
mission cycles35. In light of these data, HHQs constitute a promising 
class of compounds with transmission-blocking potential that merit 
pharmacokinetic and pharmacodynamic optimization.
In vitro HHQ resistance selection studies identified three muta-
tions in PfMDR1 (Y290F, F1072L and S1075I), which were con-
firmed by CRISRP/Cas9 editing to be causal for ABS resistance 
(Fig. 1e). PfMDR1-associated resistance also extended to the GAM 
stage (Supplementary Table  7). We note that the Pf3k collection 
of over 2,500 Pf genomes collected worldwide (www.malariagen.
net/apps/pf3k) contained no mutations with an AB > 0.2 at these 
PfMDR1 positions, suggesting that they are very rare, if not non-
existent, in the field.
Structural modelling studies indicated that all three amino 
acids co-localize in the predicted drug-binding pocket of PfMDR1 
(Fig.  3) and generally caused a closer interaction between HHQs 
and mutant PfMDR1 (Supplementary Tables 8–12). Further stud-
ies are required to determine the nature of the interactions between 
HHQs and wild-type versus mutant PfMDR1 and how this relates 
to HHQ potency.
PfMDR1, an ATP-binding cassette (ABC) transporter, can 
mediate the transport of several antimalarial drugs across the DV 
membrane30,36,37. In the highly acidic DV compartment, Pf proteases 
degrade Hb from the host RBC, providing a source of the amino 
acids required for protein synthesis and parasite growth38. This 
catabolic process triggers the formation of highly reactive haem 
moieties, which Plasmodium normally detoxifies through biomin-
eralization into chemically inert Hz crystals in the DV. Several anti-
malarials act either by binding toxic haem species and inhibiting Hz 
formation (CQ or ADQ), or in the case of artemisinins by apparently 
being activated through interaction with haem iron39. Mutations in 
PfMDR1, or the chloroquine resistance transporter PfCRT that also 
resides on the DV membrane, are known to affect in vitro parasite 
susceptibility to these drugs, presumably by affecting drug trans-
port, and are associated with an increased risk of parasite recrudes-
cence or treatment failure in patients30,40–42.
Haem fractionation studies showed a different profile in para-
sites treated with GNF-Pf-5660 as compared to CQ32, ADQ32, MQ 
or LMF (Fig. 4), indicating a distinct mode of action. HHQs did not 
directly inhibit haem conversion into Hz, but were found to reduce 
the total amounts of intracellular haem iron. These data suggest that 
HHQs act upstream of the Hb digestion pathway by interfering with 
parasite-mediated uptake of host Hb, which delivers the substrate 
for Hz formation. Western blot data showed a reduction of total Hb 
levels in HHQ-treated wild-type Dd2-B2 but not HHQ-resistant 
PfMDR1selY290F parasites (Fig. 5), supporting an effect of HHQs on 
parasite-mediated Hb endocytosis.
Parasite lines resistant to CQ, pyrimethamine and PfATP4 inhib-
itors remained sensitive to HHQs (Supplementary Table 3), whereas 
HHQ-resistant lines showed an increased Pf ABS susceptibility to 
QN, MQ, DHA and LMF (except for PfMDR1edS1075I, which showed 
no difference for LMF). Susceptibility to CQ, md-CQ, md-ADQ, 
ferroquine and piperaquine remained unaltered in HHQ-resistant 
parasites (Fig. 3 and Supplementary Table 13). QN, MQ, DHA and 
LMF are thought to interact at some level with haem but also act 
outside of the DV, raising the possibility that they might engage with 
the Hb import and catabolism process that begins with endocyto-
sis33,43–45. We speculate that the PfMDR1 mutations causing HHQ 
resistance might sensitize parasites to MQ and LMF by preventing 
their sequestration by wild-type PfMDR1 in the DV, away from 
their primary site of action46.
HHQ-resistant ABS parasites showed no substantial change in 
their susceptibility to the haem-binding drugs CQ or md-ADQ that 
act primarily in the DV41. Interestingly, PfMDR1 Y290F was also 
recently identified in selections using ACT-451840, a piperazine-
based pre-clinical candidate with low nanomolar activity against Pf 
ABS parasites and GAMs27. Studies with the ACT-213615 analogue 
earlier showed direct binding to PfMDR1, identifying it as a poten-
tial target47. The unusually high levels of resistance to both HHQs 
and ACT-451840 conferred by each of the three mutations (Figs 1e 
and 3c) suggest that both compound series probably share a similar 
mode of action. These data also evoke the possibility that PfMDR1 
might itself be a target of HHQs, a hypothesis that can be investigated 
using HHQ analogues to study protein interactions with PfMDR147 
in cultured parasites or heterologous expression systems48.
Stage-specific profiling showed that pfmdr1 is maximally tran-
scribed around the time of merozoite egress (www.PlasmoDB.org), 
suggesting that PfMDR1 is already present in early- to mid-stage 
rings, well before ABS parasites have formed their mature DV. This 
timing, supported by western blot data49, suggests that PfMDR1 
might be involved in vesicle-mediated endocytosis of host Hb from 
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from three to four independent experiments. Statistical significance was 
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the RBC en route to the developing DV. Such a role for PfMDR1 
would be consistent with our observations that HHQ inhibition 
reduces intra-parasitic total haem iron and Hz levels in trophozoites 
and reduces Hb levels in late-stage rings (Figs 4 and 5).
Further studies into the stage-dependency and subcellular site of 
action of HHQs and of drugs that are impacted by HHQ-selected 
mutations in PfMDR1, such as the first-line agent LMF, should yield 
interesting insights into how these agents act and how to leverage 
this information into identifying promising drug combinations. 
Ideally, such combinations would exert opposing selective pres-
sures on mutant and wild-type PfMDR1, in an effort to stall the 
emergence and spread of multidrug resistance. This approach is 
currently being used in clinical trials where artemether + LMF is 
being combined with ADQ (Clinical Trial NCT02453308), based 
on earlier reports that LMF and ADQ exert opposing selective pres-
sures on wild-type and mutant forms of both pfmdr1 and pfcrt40,50. 
In addition, the potent activity of HHQs against both ABS parasites 
and GAMs highlights the promise of developing this chemical class 
into a partner for future antimalarial combination therapies with 
transmission-blocking activity.
Methods
Parasite cultures and strains. Pf ABS parasites were cultured at 3–4% haematocrit 
(Hct) in human O+ RBCs in RPMI-1640 media, supplemented with 25 mM 
HEPES, 50 µ M hypoxanthine, 2 mM l-glutamine, 2 g l–1 sodium bicarbonate,  
0.5% (wt/vol) AlbuMAXII (Invitrogen) and 10 µ g ml–1 gentamycin, in 5% O2,  
5% CO2 and 90% N2 at 37 °C. For GAM cultures, Albumax was replaced with 10% 
human serum. 3D7 and Dd2 parasites were originally obtained from T. Wellems 
(NIAID, NIH). Dd2-B2 is a genetically homogenous parasite line that was cloned 
from Dd2 by limiting dilution. The NITD609-resistant parasites (generated in the 
Dd2 background) and the NF54Pfs16 line have been reported previously23,51. The 
NF54selY290F and FCB pfmdr1 knockdown line (KD1mdr1) and their corresponding 
wild-type lines were obtained in two earlier studies27,52. A list of all parasite lines 
generated in this study is provided in Supplementary Table 17. Parasite lines were 
screened by PCR for Mycoplasma every 2–3 months.
Compound screening against gametocytes. The Novartis-GNF Malaria Box 
consisted of 3,825 known inhibitors of ABS Pf parasites with a median IC50 of 
0.53 μ M (25th percentile, 0.23 μ M; 75th percentile, 1.09 μ M), as determined by a 
SYBR Green-based 72 h growth inhibition assay53, and was obtained as 10 µ l  
of 1 mM stock solution in 100% DMSO. These compounds were independently 
screened against early- and late-stage GAMs (stages I and IV, respectively), as 
described below in the two subsequent sections. Screening was performed  
with the NF54Pfs16 line that expresses a green fluorescent protein (GFP)–LUC 
fusion under the pfs16 promoter that is active throughout gametocytogenesis23. 
Earlier studies have reported the optimization of high-throughput early- and  
late-stage GAM screens using this line in LUC- or GFP-based assays54–56. For the 
LUC-based screens with early-stage GAMs, compounds were diluted 1.5-fold in 
100% DMSO and further diluted in water to a final assay concentration of 2.6 µ M  
in 0.4% DMSO. Hits, defined as compounds that showed ≥ 50% inhibition  
at 2.6 µ M, were retested for confirmation at 2.6, 1.3 and 0.65 µ M. For the GFP  
high-content imaging-based screens with late-stage GAMs, compounds were 
diluted to a final assay concentration of 2 µ M in 0.4% DMSO and screened in 
triplicate. Due to limitations in the availability of the screening hits, not all hits 
could be retested for confirmation. Fresh batches of 125 hits from the late-stage 
screens were obtained as 2 mM 100% DMSO stock solutions from GNF-Novartis, 
and 24 additional hits were purchased as solids from various commercial  
sources (Supplementary Table 1).
Luciferase-based early-stage gametocyte inhibition assay. LUC-based 
screening with stage I GAMs was conducted as previously described13. Briefly, 
NF54Pfs16 parasites were synchronized by two cycles of 5% sorbitol treatment, and 
gametocytogenesis was induced by applying multiple known stimulant stress 
factors (a drop in Hct, higher parasitaemia and spent media). After one replication 
cycle under these conditions, the resulting stage I GAMs and asexual rings were 
separated from residual Hz-containing and later-stage GAMs by paramagnetic 
purification over a MACS column (Miltenyi Biotech). Medium containing 50 mM 
N-acetyl-d-glucosamine (to eliminate ABS parasites) was provided and refreshed 
daily. On day 1 of gametocytogenesis, which corresponds to day 0 of the early-stage 
GAM assay, the parasitaemia was adjusted to 10% and the Hct was reduced to 
0.5%. Parasites were seeded under sterile conditions to a volume of 45 μ l per well in 
384-well white luminescence plates (CulturPlate, PerkinElmer) using a Multidrop 
dispenser (Thermo Scientific). Experimental compounds were added to the  
plates at the desired concentrations in a volume of 5 μ l with a final DMSO 
concentration of 0.4% per assay well. Two columns of each plate were used as  
in-plate controls, containing 0.4% DMSO (negative control, 0% inhibition) or  
5 μ M puromycin (positive control, 100% inhibition), respectively. Plates were 
sealed with gas-exchange membranes (Breathe-easy, Sigma) and incubated for  
72 h at 37 °C in 5% O2, 5% CO2 and 90% N2. On day 4 of gametocytogenesis,  
25 μ l of supernatant was removed from each well and replaced with 15 μ l Steadylite 
solution (luciferase assay kit, PerkinElmer), using a Biomek FX (Beckman Coulter) 
high-throughput liquid handling system. Plates were sealed and incubated  
at room temperature for 60 min to allow for complete cell lysis, after which the 
plates were read using a MicroBeta Trilux luminometer (PerkinElmer).
Image-based late-stage gametocyte inhibition assay. The effect of compounds  
on stage IV GAMs was determined using an image-based assay54. Briefly, at  
day 8 post-induction, stage IV NF54Pfs16 GAMs were purified over a MACS column 
and adjusted to 10% parasitaemia and 0.1% Hct. Parasites were dispensed in  
45 µ l volumes into 384-well imaging plates containing 5 µ l of diluted compounds 
per well, with a final DMSO concentration of 0.4%. After 72 h incubation at 37 °C 
in 5% O2, 5% CO2 and 90% N2, 5 µ l of 0.07 µ g ml–1 MitoTracker Red CM-H2XRos 
(Invitrogen) in PBS was added and incubated overnight. Parasites were imaged 
on an Opera QEHS confocal imaging system (PerkinElmer). Image analysis 
using an Acapella-based script determined the number of viable mature GAMs 
per imaged area of each well, as described previously54. Controls included 5 µ M 
puromycin. Experiments were performed with triplicate technical replicates on 
three independent occasions.
Gametocytocidal potency. Stage-specific potency data were generated  
using LUC and imaging-based assays for early- and late-stage GAMs, respectively, 
as described above. Relevant parasite stages were exposed to serial dilutions of 
compounds, typically with a maximal concentration of 40 µ M, in 14 to 21 serial 
dilution steps with three concentrations per log dose. Assays were repeated on 
two independent occasions. Reference compounds (puromycin, DHA, CQ, 
pyrimethamine and primaquine) were used as positive and negative controls  
and yielded IC50 values (Supplementary Table 2) that were consistent with  
earlier reports13,55.
Imaging-based ABS high-throughput assay. Hit compounds with confirmed 
gametocytocidal activity were also evaluated for ABS activity using our imaging-
based high-throughput assay57. Briefly, sorbitol-synchronized Pf parasite lines  
were seeded at 2% parasitaemia and 0.3% Hct in 384-well clear-bottom imaging 
plates (CellCarrier, PerkinElmer). For this work we used 3D7 (drug-sensitive),  
Dd2 (resistant to CQ, MQ and pyrimethamine) and NITD609-RDd2 clone #2 
(resistant to the PfATP4 inhibitor now termed KAE60951). Parasites were incubated 
with compounds for 72 h at 37 °C in 5% O2, 5% CO2 and 90% N2. Parasites were 
then permeabilized using 0.01% Triton-X100 and 0.001% saponin plus 5 mM 
EDTA and stained using 0.5 μ g ml–1 4′ ,6-diamidino-2-phenylindole (DAPI). Plates 
were kept at room temperature in the dark for a minimum of 6 h and were then 
imaged on an Opera confocal microplate system (PerkinElmer) using a 20× water 
objective with 405 nm excitation and 420–490 nm bandpass emission filter and 
an exposure time of 80 ms. The experiment was performed with two independent 
cultures. Parasite numbers, calculated based on spot size, intensity and fluorescence 
over background, were determined using Acapella software57.
HEK293 cytotoxicity. Cytotoxicity of the selected gametocytocidal hits was 
assessed against the HEK293 human embryonic kidney cell line (ATCC #CRL-1573),  
maintained in DMEM medium (Life Technologies) supplemented with 10% fetal 
calf serum (Gibco). Cells were trypsinized, seeded into sterile 384-well plates 
(Falcon) at 2,000 cells per well in 45 μ l medium and incubated overnight at 37 °C 
in 5% CO2 and 95% humidity to allow adhesion. A resazurin-based metabolic 
assay was used to determine cell viability58. Briefly, test compounds were serially 
diluted and added to the plates to generate a dose-response with a maximal 
concentration of 40 μ M, in wells containing a final DMSO concentration of 0.4%. 
Plates were incubated for 72 h under standard conditions, after which the medium 
was removed and replaced with 35 μ l of serum-free DMEM containing 44 μ M 
resazurin. The plates were then incubated for a further 4–6 h under standard 
conditions before being read on an EnVision plate reader (PerkinElmer) using 
530 nm/595 nm fluorescence excitation/emission settings. Two biological replicates 
were performed. The cells were certified by ATCC as being Mycoplasma-free  
at source.
Dual gamete formation assay. The effects of GNF-Pf-5310, GNF-Pf-5640,  
GNF-Pf-5660 and GNF-Pf-5668 on the formation of male and female gametes  
were determined using the DGFA56. Compounds were tested across a range  
of 12 concentrations (0.84 nM to 20 μ M) and IC50 values were calculated using 
nonlinear regression (Graphpad Prism 6). Briefly, stage V GAMs were exposed to 
compounds for 24 h, after which gamete formation was triggered in the presence 
(carry-over format) or absence (wash-out format, three washes) of compound. 
Male gamete formation was assessed by automated microscopic detection of 
exflagellation and female gamete formation was evaluated by live immunostaining 
for Pfs25 surface expression59. Data were calculated from four biological replicates, 
with methylene blue included as a control.
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Membrane-feeding assay. Late-stage GAMs (12 days post GAM induction)  
were treated for 3 days with GNF-Pf-5660, GNF-Pf-5668 or GNF-Pf-5310 at  
1× or 3× their late-stage GAM IC50 values (with daily medium changes including 
compound refreshment) and then maintained without compound for another 
4 days. Methylene blue was used as a positive control at a concentration of 3× the 
GAM IC50. GAMs treated with 0.25% DMSO were used as the negative control23. 
Stage V GAM cultures at 50% Hct and 0.01–0.16% parasitaemia were exposed to 
A. stephensi mosquitoes (4–6 days post-emergence) for 30 min using an artificial 
membrane feeding apparatus. For each compound and controls, two containers 
holding 25 to 35 parasite-exposed mosquitoes each were maintained at 26 °C,  
78% relative humidity with a 12 h day/night cycle. Seven or eight days post  
feeding (for experiments 1 and 2, respectively), the midguts from blood-fed  
female mosquitoes (n = 17–21 per container) were dissected and stained with  
0.2% mercurochrome to count oocyst numbers. Infection prevalence was defined 
as the percentage of mosquitoes harbouring one or more midgut oocysts, and 
infection intensity was defined as the mean number of oocysts per mosquito. 
Midguts of mosquitoes fed with DMSO vehicle-treated GAMs showed an average 
of 19 oocysts. All samples were blinded for both dissection and oocyst counting.
In vivo potency of HHQs on ABS parasites. For our 4-day Peters test, four 
female CD-1 mice (Taconic; 5 weeks old, weighing 22–25 g) per group were 
infected intraperitoneally with 1 × 106 P. berghei ANKA MRA868 ABS parasites. 
Treatments with 70 or 100 mg kg–1 of GNF-Pf-5660 or GNF-Pf-5668, 30 mg kg–1 
DHA or solvent-only (20% DMSO in water) were administered intraperitoneally 
2 h, 24 h, 48 h and 72 h after infection. Blood-stage parasitaemias were assessed 
at 96 h post infection by microscopy. Plasma compound concentrations were 
not measured. All experiments involving mice were reviewed and approved by 
the Columbia University Institutional Animal Care and Use Committee. Sample 
size was determined in accordance with published literature60,61 and to minimize 
the number of animals under experiment. All research animals were randomly 
allocated into treated and control groups and groups were blinded for collection 
and analysis of data. This research is compliant with federal regulations detailed 
in the Animal Welfare Act (AWA) (7 U.S.C. 2131, seq.) and the Health Research 
Extension Act of 1985 (Public Law 99-158).
In vivo transmission-blocking effect of HHQs. To assess the in vivo 
transmission-blocking effect of HHQs, four female CD-1 mice were treated with 
two doses of 100 mg kg–1 GNF-Pf-5660 or GNF-Pf-5668, 30 mg kg–1 DHA, or 
solvent only. Doses were spaced 12 h apart, starting when blood-stage parasitaemia 
after infection with 5 × 106 P. berghei ANKA MRA868 parasites reached 1%, to 
measure drug impact only on GAMs. We note that in P. berghei GAMs develop and 
become transmissible within a 24 h period. Twelve hours after the last dose, both 
blood-stage parasitaemia and the level of inhibition of male GAM exflagellation 
were assessed. For the exflagellation test, a tail blood sample was collected in a 
heparinized tube, mixed with ookinete medium (RMPI medium, 25 mM HEPES, 
50 mg l–1 hypoxanthine, 2 g l–1 sodium bicarbonate and 0.5% Albumax) containing 
100 μ M xanthurenic acid and evaluated by microscopy after a 10 min incubation 
at 20 °C. Shortly afterwards, 25–30 A. stephensi mosquitoes were fed on individual 
mice that were anaesthetized by intraperitoneal injection of 200 μ l of a mixture 
of ketamine (17.5 mg ml–1) and xylazine (2.5 mg ml–1). Unfed mosquitoes were 
removed, and engorged mosquitoes were fed daily with a 10% sugar solution and 
maintained at 20 °C at 80% humidity for 10 days. Midguts of 10–20 mosquitoes 
fed per mouse were then dissected and stained with 0.5% mercurochrome for 
oocyst counting by microscopy. Data were analysed in a similar manner as for the 
membrane-feeding assay (see section 'Membrane-feeding assay').
Selections for HHQ resistance. To select for Pf resistance to GNF-Pf5640,  
GNF-Pf-5660 and GNF-Pf-5668, triplicate flasks of 109 Dd2-B2 parasites were 
exposed to compounds at 5× their ABS IC50 values. Briefly, medium containing 
the compound of interest was refreshed daily during the first 7 days, while cultures 
were carefully monitored to avoid overgrowth and ensure that sensitive parasites 
were effectively cleared. RBCs (0.5% Hct) were added on day 7 and the total 
culture volume was reduced by 25% each subsequent week until a 5 ml volume was 
obtained. Fresh RBCs (1% Hct) were added on a weekly basis from day 14 onwards, 
always maintaining a total Hct level of 3–4%. Once cultures appeared negative,  
the medium containing the compound of interest was refreshed every other day 
until at least 1% parasitaemia was reached, after which medium was replenished 
daily. Resistant clones were obtained by limiting dilution62. DNA was extracted 
with the DNAeasy Blood & Tissue kit (Qiagen) and sequenced using paired-end 
reads on a Illumina HiSeq 2500 platform27. Whole-genome sequence analysis was 
performed at UC San Diego and Columbia University, using previously described 
customized pipelines and the GATK toolkit26,63,64.
Gene editing. pfmdr1 point mutations were introduced into Dd2-B2 parasites 
using a two-plasmid CRISPR–Cas9 targeted gene-editing strategy27. The Cas9  
plasmid encoded the Cas9 nuclease, a single guide RNA (5′ -GAAAATTAAT 
GTCCTTAAA for F1072L and S1075I and either 5′ -ATTTTAGTTTCT 
TATGCATT or 5′ -TTACATATAGGTTTAATAAA for Y290F) that complexes the 
Cas9 nuclease with the target sequence, and a human dhfr cassette that mediates 
resistance to the WR99210 selection agent27. The donor plasmid contained the 
homologous pfmdr1 sequence (nucleotides 1871–3421 of the Pf3D7_0523000 
coding sequence for the mutations at amino acid position 1072 and 1075,  
and nucleotides 383–1034 for the mutation at amino acid position 290)  
harbouring the mutation of interest, as well as eight synonymous mutations 
to prevent the Cas9 nuclease from cleaving the edited gene sequence, and the 
blasticidin S deaminase gene cassette that mediates resistance to blasticidin.  
Ring-stage cultures were transfected with the Cas9 and donor plasmids as 
described in ref. 27. At 24 h after electroporation, blasticidin (2 μ g ml–1) and 
WR99210 (2.5 nM) selection was initiated. The medium containing these  
drugs was refreshed daily for 12 days. From day 13 onwards, cultures were 
maintained under blasticidin pressure until parasites were microscopically 
observed. pfmdr1-modified clones were obtained by limiting dilution, and gene 
editing was verified by PCR and Sanger sequencing. Transfections were performed 
in duplicate on one to three occasions until editing was achieved.
Drug susceptibility profiling of HHQ-resistant lines in ABS parasites. To 
assess antimalarial susceptibilities, we exposed ring-stage cultures (at an initial 
parasitaemia of 0.2% and 1% Hct) for 72 h to a range of ten concentrations  
(plated in duplicate), in a 96-well format. Dd2-B2 parasites were included  
as a parental control. Parasite survival was assessed by flow cytometry on an  
Accuri C6 (BD Biosciences) using SYBR Green and MitoTracker Deep Red FM 
(Life Technologies) as nuclear and vital dyes65. Assays were performed on three 
to ten separate occasions (Supplementary Table 5). Growth inhibition data were 
plotted using nonlinear regression to calculate IC50 values (using Graphpad  
Prism 6). IC50 values were compared between the selected or edited lines and their 
parental controls (Dd2-B2, FCB or NF54Pfs16) using an unequal variance t-test,  
also referred to as Welch’s t-test, to correct for differences in the number of 
repeats per group. A Bonferroni–Dunn correction for multiple comparisons was 
performed when applicable.
Drug susceptibility of HHQ-resistant lines at GAM stages. The NF54selY290F line 
was tested together with a wild-type NF54 parental control for GAM susceptibility 
to the three HHQs using a previously described parasite lactate dehydrogenase-
based assay66.
PfMDR1 modelling. The Pf 3D7 PfMDR1 amino acid sequence (accession no. 
XP_001351787) was used to develop a structural model. Membrane protein 
topology was predicted using TOPCONS67. Residues 51–350 and 781–1090, based 
on the topology prediction, were used for homology detection and structure 
prediction with the HHpred tool68. The best ranked hits (Prob = 100) were 
considered and the ABC transporter structure of Thermotoga maritima (PDB 
4Q4H) was used to model PfMDR1, using MODELLER because of its apo state69. 
PfMDR1 TMDs were refined using WinCoot70 and assembled by superimposition 
on the 4Q4H template using the visualization software Yasara71. Docking 
simulations of compounds GNF-Pf-5640, GNF-Pf-5660 and GNF-Pf-5668 were 
performed using DockingServer72, with residues 290, 1072 and 1075 seeded  
in a 15 Å box at default conditions.
Haem fractionation assay. Haem fractionation analysis was performed as 
described in ref. 32. Briefly, early ring-stage sorbitol-synchronized Dd2-B2 
and PfMDR1selY290F parasites were exposed to GNF-Pf-5660, MQ or LMF at 
concentrations corresponding to 0.1, 0.25, 0.5, 1 and 2× the ABS IC50 (ref. 32).  
After a 32 h incubation, cells were saponin-lysed and trophozoites were subjected 
to a series of lysis, solubilization and differential centrifugation steps to obtain 
fractions that contain Hb, free haem or Hz. The UV–visible spectra of haem as 
Fe(iii)haem-pyridine were analysed in each of these fractions and compared 
to a haem standard curve for accurate quantification. These quantities were 
subsequently normalized using the number of analysed cells, as determined  
by flow cytometry of an aliquot of exposed cells. Two-tailed t-tests were used  
to assess significance32.
Western blotting. Sorbitol-synchronized parasites were exposed to 5× the IC50 of 
GNF-Pf-5660, WR99210, MQ or LMF for 5 h, starting at the late-ring stage, that 
is, before parasites entered the mid-stage trophozoites that have maximal rates of 
Hb degradation and Hz formation. RBCs were then saponin-lysed and parasites 
washed five times in 1× PBS. The parasite pellet was solubilized in SDS–PAGE 
sample buffer and sonicated for ten cycles of 10 s. Samples were then boiled for 
10 min at 90 °C and 3.5 × 106 parasites were loaded on a 4–20% Criterion TGX 
precast midi protein gel (Bio-Rad). After transferring the resolved proteins to a 
nitrocellulose membrane, membranes were blocked for 1.5 h in TBS-Tween 0.1% 
(TBS-T) + 5% blocking-grade blocker (Bio-Rad). Membranes were cut in two at the 
37 kDa marker position, and the lower and upper parts were incubated overnight 
at 4 °C in TBS-T + 1% blocker and a 1:5,000 dilution of rabbit anti-human Hb 
antibody (Sigma #H4890, lot 124M4788V) or a 1:2,000 dilution of β -actin 
monoclonal antibody (Fisher #AM4302), respectively. After washing in TBS-T, 
membranes were incubated in TBS-T + 1% blocker and a 1:10,000 dilution of goat 
anti-rabbit IgG conjugated to horseradish peroxidase (GE Healthcare #RPN4301) 
to detect Hb, or a 1:10,000 dilution of sheep anti-mouse Ig coupled to horseradish 
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peroxidase (GE Healthcare #NXA931) to detect β -actin. Proteins bands were 
detected using the Pierce ECL western blotting substrate (ThermoScientific), blue 
basic autoradiography film (Genemate) and a Nikon X-OMAT 2000. Hb band 
intensities were calculated in ImageJ, normalized for loading with the β -actin 
signal, and compared to untreated controls. Experiments were repeated on three to 
four independent occasions.
Data availability. All data generated or analysed during this study are included in 
this published article and its Supplementary Information. Requests for materials 
should be addressed to the corresponding author.
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manuscript, all fields must be completed for clarity. 
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, 
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    Experimental design
1.   Sample size
Describe how sample size was determined. The in vitro drug assays described in this manuscript were performed 3-12 
times. This number of independent repeats exceeds standard number of 
2-3 described in most studies. A minimum of 3 independent repeats is 
required to assess for a significant shift. The in vivo efficacy and 
transmission blocking data were performed on 2 different occasions using 
4 mice per group, per standard protocols and to minimize the number of 
animals under experiment. Details regarding sample size of these and all 
other performed experiments are provided in the Methods section, the 
legends of the figures and in the supplementary files.
2.   Data exclusions
Describe any data exclusions. All data generated during this study are shown in the manuscript.
3.   Replication
Describe whether the experimental findings were reliably reproduced. All attempts at replication were successful. Data are represented as means 
with the corresponding standard error of the mean to indicate biological 
variation.
4.   Randomization
Describe how samples/organisms/participants were allocated into 
experimental groups.
Outbred CD1 mice and mosquitoes were randomly allocated into treated 
and control groups for the in vivo efficacy and transmission-blocking 
experiments.
5.   Blinding
Describe whether the investigators were blinded to group allocation 
during data collection and/or analysis.
Groups of mice (3 treated groups vs 1 untreated group) were blinded for 
collection and analysis of data when used for in vivo drug efficacy and 
feeding to mosquitoes for transmission-blocking studies.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods 
section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample 
was measured repeatedly. 
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted
A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this study. Drug susceptibility data generation and statistical analysis were performed 
using GraphPad Prism 6 as mentioned in the respective paragraphs in the 
Methods section. Whole-genome sequencing analysis were performed 
using existing published tools as described in the manuscript (lines 
692-694)
For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon 
request.  The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of unique 
materials or if these materials are only available for distribution by a 
for-profit company.
There are no restrictions on availability of parasite strains or 
hexahydroquinoline compounds used in this study.
9.   Antibodies
Describe the antibodies used and how they were validated for use in 
the system under study (i.e. assay and species).
All antibodies and their origin were purchased at official suppliers as listed 
in the manuscript on lines 764-769 and are summarized below 
• anti-human polyclonal hemoglobin antibody produced in rabbit (Sigma 
#H4890, lot 124M4788V)  
• goat anti-rabbit IgG horseradish peroxidase (GE Healthcare #RPN4301) 
• anti-mouse beta-actin monoclonal antibody (AC-15) (Fisher #AM4302) 
• sheep anti-mouse Ig, horseradish peroxidase linked whole antibody (GE 
Healthcare #NXA931) 
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10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. All parasite lines that were not generated in this study are described on 
lines 534-539
b.  Describe the method of cell line authentication used. Cell lines were verified by PCR and Sanger sequencing of different loci 
known to differ between parasite lines (such as PfMDR1 for example (see 
line 712-713)).
c.  Report whether the cell lines were tested for mycoplasma 
contamination.
Original cell lines were tested by PCR for Mycoplasma contamination every 
2 to 3 months (see line 539).
d.  If any of the cell lines used in the paper are listed in the database 
of commonly misidentified cell lines maintained by ICLAC, 
provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived materials used in 
the study.
Animals used for the in vivo studies: Mus musculus, CD-1 strain, female, 
22-24 grams (as mentioned on lines 653-654).
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population characteristics of the 
human research participants.
The study did not involve human research participants.
